Nageeb
Zagazig, Sharqia Province, 002, Egypt
NCT Number: NCT03926273
Several neuropeptides have concerned with epilepsy pathogenesis, ghrelin showed an anticonvulsant effect. There is a potential relation between its level and antiepileptic drugs (AED) response.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Zagazig, Sharqia Province, 002, Egypt
Several neuropeptides have concerned with epilepsy pathogenesis, ghrelin showed an anticonvulsant effect. There is a potential relation between its level and antiepileptic drugs (AED) response. Objective: to evaluate ghrelin effect in adult epileptic patients and in response to AED. Methods: This case control study included 40 adult epileptic patients and 40 healthy controls. Participants were subjected to history taking of seizure semiology, full general and neurological examination, electroencephalography and cranial CT or MRI. Fasting serum acylated ghrelin (AG) and unacylated ghrelin (UAG) and urine AG levels were estimated to all participants by enzyme - linked immunosorbent assay (ELIZA).
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: 6 months
evaluation of the effect of Serum ghrelin in adult epileptic patients and in their response to anti- epileptic drugs
Time frame: 6 months
evaluation of the effect of Urine ghrelin in adult epileptic patients and in their response to anti- epileptic drugs
Zagazig University
Other Gov
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06352372
Autism Spectrum Disorder, Autistic Disorder
Phoenix, Arizona, United States
View Trial DetailsNCT06546410
Brain Diseases, Central Nervous System Diseases
Liverpool, United Kingdom
View Trial DetailsNCT07689084
Brain Diseases, Central Nervous System Diseases
Marburg, Hesse, Germany
View Trial DetailsNCT07689617
Brain Diseases, Central Nervous System Diseases
Elâzığ, Turkey (Türkiye)
View Trial Details